Psychedelic Spotlight News

  • BUY Ratings, New Partnerships & Government Awards ( Mydecine, ENBI, SILO, DMT, BRAXIA, DRUG)

    Listen, Videos

    NEW BUY RATINGS, More Partnerships and Government Awards for psychedelic inspired companies! In this episode, we’ll take a look at the smaller psychedelic medicine companies such as Mydecine, Entheon Biomedical, Braxia, Small Pharma, Silo Therapeutics and Bright Minds Sciences.

    Enjoy the episode!

    Timestamps:

    0:00 – Intro
    0:44 – Mydecine (MYCO/ MYCOF) Unveils Artificial Intelligence Drug Discovery Program
    2:21 – Braxia Scientific (OTC:BRAXF, CSE: BRAX) Awarded Government of Canada Funding To Complete The First Ever Ketamine Clinical Trial Testing For Bipolar Depression
    3:51 – Partnership Between Entheon / SILO Pharma (OTC:ENTBF, CSE:ENBI) (OTC: SILO)
    6:59 – Bright Minds (OTC: BMBIF, CSE: DRUG) Announces Application to List on Nasdaq
    8:43 – Small Pharma (TSXV: DMT) – Price Target of C$5

    Links:

    Mydecine (OTC: MYCOF, NEO: MYCO) Unveils Artificial Intelligence Drug Discovery Program, in conjunction with the University of Alberta:
    https://www.psychedelicfinance.com/articles/mydecine-unveils-artificial-intelligence-drug-discovery-program

    Braxia Scientific (OTC:BRAXF, CSE: BRAX) Awarded Government of Canada Funding To Complete The First Ever Ketamine Clinical Trial Testing For Bipolar Depression:
    https://braxiascientific.com/news/braxia-scientific-awarded-government-of-canada-funding-to-complete-first-of-its-kind-ketamine-clinical-trial-for-bipolar-depression/

    Partnership Between Entheon / SILO Pharma (OTC:ENTBF, CSE:ENBI) (OTC: SILO):
    https://thecannabisstock.com/2021/06/17/entheon-biomedicals-wholly-owned-subsidiary-halugen-life-sciences-and-silo-wellness-announces-psychedelics-genetic-test-kit-partnership/

    Bright Minds (OTC: BMBIF, CSE: DRUG) Announces Application to List on Nasdaq:
    https://psilocybinalpha.com/news/bright-minds-biosciences-announces-application-to-list-on-nasdaq

    Small Pharma (TSXV: DMT) – Roth Capital Initiates Coverage On Small Pharma with Buy Rating, Announces Price Target of C$5:
    https://www.benzinga.com/news/21/06/21452074/roth-capital-initiates-coverage-on-small-pharma-with-buy-rating-announces-price-target-of-c-5

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Website: https://thepsychedelicinvestor.com/
    Music: www.bensound.com
    editing:@themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Mydecine #Entheon #MYCO